Status | Study |
Not yet recruiting |
Study Name: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Condition: Adult T-Cell Leukemia/Lymphoma Anaplastic Large Cell Lymphoma, Date: 2017-04-10 Interventions: Drug: Brentuximab Vedotin Give |
Recruiting |
Study Name: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm Hepatosplenic T-Cell Lymphoma Date: 2017-03-01 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Risk Stratification of Nodal PTCL Condition: Peripheral T-Cell Lymphoma, Not Otherwise Specified Angioimmunoblastic T-cell Lymphoma Date: 2017-01-31 |
Recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Condition: Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Date: 2017-01-09 Interventions: Biological: Biological Therapy |
Not yet recruiting |
Study Name: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Condition: Adenoid Cystic Carcinoma Adnexal Carcinoma Apocrine Carcin Date: 2016-11-30 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Condition: Hodgkin Disease Lymphoma, Large-Cell, Anaplastic Date: 2016-10-18 Interventions: Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
Recruiting |
Study Name: Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + Condition: ALCL Date: 2016-09-07 Interventions: Other: Blood sample |
Not yet recruiting |
Study Name: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Condition: Anaplastic Large Cell Lymphoma, ALK-Positive Systemic Date: 2016-03-29 Interventions: Drug: Brentuximab Vedotin Give |
Recruiting |
Study Name: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Condition: Adult Nasal Type Extranodal NK/T-Cell Lymphoma Adult T-Cell Leukemia/Lymphoma Date: 2016-01-08 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Condition: ALK Positive BCL6 Positive Recurrent Date: 2015-10-08 Interventions: Other: Laboratory Biomarker Analysis |